Home / Business / Stock Alert – Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Stock Alert – Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

collected by :John Locas

follow the latest news about business from different sites most famous technicals /Chris Lau by 2017-01-11 at 1:1

as declared in

Hold Valeant Pharmaceuticals – Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Hold Valeant Pharmaceuticals - Valeant Pharmaceuticals International, Inc. (NYSE:VRX)*/

– Value investors face paper losses when picking a bottom for a stock.The more the stock falls, the more discounted the stock looks from its intrinsic value.Valeant Pharmaceuticals (NYSE:VRX) faced so many headwinds in 2016 that its only accomplishment on the market was not closing at a yearly low.
.

read more from here

Valeant Pharmaceuticals – 3 Paths To A Multi-Bagger – Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Valeant Pharmaceuticals - 3 Paths To A Multi-Bagger - Valeant Pharmaceuticals International, Inc. (NYSE:VRX)*/

– Debt levels are high, but could be managed and debt refinancing is an option as well.Valeant (NYSE:VRX) is a hated stock with a very cheap valuation (due to bankruptcy fears, perhaps a bit overblown as you will see below).I believe Valeant is currently near the point of maximum pessimism, which provides investors with the maximum return potential.
.

read more from here

Stock Alert – Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Stock Alert – Valeant Pharmaceuticals International, Inc. (NYSE:VRX)*/

– Valeant Pharmaceuticals International, Inc.’s (VRX)’s Stock Price Trading Update:Valeant Pharmaceuticals International, Inc.’s (VRX) ended its day with a gain of 0.39% and finalized at the price of $15.35.During its last trading session, Stock traded with the total exchanged volume of 9.52 million shares.The average volume stands around 18.33 million shares.
.

read more from here

Valeant Is A Strong Acquisition Target – Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Valeant Is A Strong Acquisition Target - Valeant Pharmaceuticals International, Inc. (NYSE:VRX)*/

– Valeant (NYSE:VRX) has many challenges going forward, but there is still fundamental value in the company’s portfolio.If Valeant’s market cap falls significantly below where it currently is, the company may make for a good acquisition target.Even now at around $5 billion in equity value and $30 billion in debt, Valeant’s enterprise value is less than 9x EBITDA while the going rate for pharmaceutical acquisitions is a 15x EBITDA multiple.
.

read more from here

read more
visit us

business

Check Also

Amazon Prime customers to get sales at Whole Foods Markets in bid to lure on line shoppers to stores picture-16756-310x165

Amazon Prime customers to get sales at Whole Foods Markets in bid to lure on-line shoppers to stores

Amazon Prime customers to get sales at Whole Foods Markets in bid to lure on-line …